Due to its psychiatric side effects, the FDA advises that Singulair should not be the first choice treatment for mild allergies, and healthcare providers should weigh the potential risks and benefits before prescribing Singulair for asthma.
Read More »Tag: montelukast
NCHR Testimony on Singulair and Neuropsychiatric Side Effects
September 27, 2019. Singulair has serious side effects and we need much better data to determine the likely benefit and risk of harm for patients. FDA has an important role to play in encouraging this research. In the meantime, patients, parents, and clinicians must be given clear information about the risks so that they can make an informed decision about whether to use montelukast (Singulair).
Read More »